Tango Therapeutics Executive Exercises Stock Options
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2026
0mins
Should l Buy TNGX?
Source: Fool
- Stock Option Exercise: Crystal Adam, President of R&D at Tango Therapeutics, exercised 27,000 stock options, resulting in a transaction value of approximately $572,000, which underscores her confidence in the company's future and reflects the strong performance of its stock.
- Transparent Trading Plan: This transaction was executed under a pre-scheduled 10b5-1 trading plan established on October 27, 2025, indicating that these sales were planned in advance rather than being a spontaneous reaction to company news, thereby enhancing investor confidence.
- Ongoing Equity Exposure: Following this transaction, Adam retains 112,622 common shares and 433,500 stock options, demonstrating her continued commitment to the company's performance and investment, which further bolsters market trust in Tango's future.
- Improved Financial Condition: Tango Therapeutics reported a net loss of $101.6 million for 2025, an improvement from the $130.3 million loss in 2024, while ending the year with $343 million in cash and marketable securities, ensuring sufficient funding for its R&D projects in the coming years.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNGX
Wall Street analysts forecast TNGX stock price to fall
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 26.640
Low
12.00
Averages
13.67
High
15.00
Current: 26.640
Low
12.00
Averages
13.67
High
15.00
About TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The Company is focused on clinical development of two methylthioadenosine phosphorylase (MTAP)-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of the Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tango Therapeutics Appoints New CFO and Executives to Accelerate Growth
- Executive Appointments: Tango Therapeutics announced the appointment of Matthew Gall as CFO, Yen-Ching Chua as Chief Development Operations Officer, and Janice Kapty, PhD as SVP of Corporate Strategy and Project Leadership, aiming to enhance the company's leadership in precision cancer drug development.
- Financial Leadership Change: Matthew Gall will take over as CFO effective April 15, 2026, succeeding Daniella Beckman, and with his extensive experience in biotechnology finance and capital raising, he is expected to drive further development of the company's financial strategy.
- Clinical Operations Enhancement: Yen-Ching Chua will assume her role on June 1, 2026, overseeing clinical operations and compliance management, and her global experience from Novocure and Novartis is anticipated to improve the efficiency and quality of the company's clinical trials.
- Project Management Optimization: Dr. Janice Kapty will be responsible for project management of vopimetostat and other therapies, and her background at Arvinas and Bristol Myers Squibb is expected to ensure successful project advancement and strategic implementation.
See More
Revolution's Cancer Drug Shows Promising Results in Trials
- Clinical Trial Results: Revolution's experimental cancer drug daraxonrasib demonstrated statistically significant improvements in progression-free survival and overall survival in patients with metastatic pancreatic ductal adenocarcinoma, with a median survival of 13.2 months compared to 6.7 months for chemotherapy, indicating substantial clinical relevance.
- Market Reaction: Following the announcement, Revolution's shares surged by 41%, reflecting strong market enthusiasm for its research findings, with RBC Capital labeling the drug a 'game changer', potentially attracting more investor interest in the company.
- Competitor Dynamics: Erasca's shares fell by 7% after the positive data from Revolution, despite its own focus on developing therapies for pancreatic cancer, indicating that market confidence in Revolution's results may negatively impact Erasca's outlook.
- Analyst Ratings: While Jefferies maintained a 'Buy' rating and a $21 price target for Erasca, the lack of significant improvement in market expectations suggests that the heightened focus on Revolution could overshadow Erasca's future performance.
See More
Tango Therapeutics Executive Exercises Stock Options
- Stock Option Exercise: Crystal Adam, President of R&D at Tango Therapeutics, exercised 27,000 stock options, resulting in a transaction value of approximately $572,000, which underscores her confidence in the company's future and reflects the strong performance of its stock.
- Transparent Trading Plan: This transaction was executed under a pre-scheduled 10b5-1 trading plan established on October 27, 2025, indicating that these sales were planned in advance rather than being a spontaneous reaction to company news, thereby enhancing investor confidence.
- Ongoing Equity Exposure: Following this transaction, Adam retains 112,622 common shares and 433,500 stock options, demonstrating her continued commitment to the company's performance and investment, which further bolsters market trust in Tango's future.
- Improved Financial Condition: Tango Therapeutics reported a net loss of $101.6 million for 2025, an improvement from the $130.3 million loss in 2024, while ending the year with $343 million in cash and marketable securities, ensuring sufficient funding for its R&D projects in the coming years.
See More
Canaccord Genuity Initiates Coverage of Tango Therapeutics with Buy Rating
- Coverage Initiation: Canaccord Genuity launched coverage of Tango Therapeutics (TNGX) on Thursday with a Buy recommendation and a $30 price target, citing significant upside potential from three trial readouts expected this year.
- Clinical Trial Advantage: Analyst John Newman highlighted Tango's strategy to combine its lead asset vopimetostat with two RAS inhibitors from Revolution Medicines (RVMD) for pancreatic cancer, which is expected to enhance efficacy compared to competitors.
- Sales Forecast: The analyst projects approximately $800 million in peak U.S. sales for vopimetostat in treating MTAP-deleted non-small cell lung cancer, with another readout from a Phase 1/2 monotherapy trial anticipated in 2026.
- Maturity of Data Expected: Newman argued that Tango expects the clinical data to be quite mature by 2026, focusing on overall response rates and progression-free survival, which will provide meaningful support for vopimetostat's clinical profile.
See More
Analysis of Insider Stock Transaction at Tango Therapeutics
- Insider Stock Sale: Adam Crystal, President of R&D at Tango Therapeutics, sold 20,251 shares on March 5, 2026, for a total of $303,765, indicating a continued liquidity management strategy within the company.
- Ownership Proportion Change: This transaction represented 15.24% of Crystal's direct holdings, significantly higher than his earlier median of 3.42%, suggesting an increasing trend in his share sales in recent transactions.
- Company Financial Overview: Tango Therapeutics reported a trailing twelve-month revenue of $62.38 million, with a net income of -$101.59 million; however, its stock price surged 1,220% over the past year, reflecting strong market confidence in its cancer treatment drugs.
- Clinical Trial Progress: The company achieved positive results in clinical trials for MTAP-deleted pancreatic cancer, driving a 36% stock price increase, while holding $343 million in cash, ensuring operational stability during its clinical phase.
See More
Tango Therapeutics Executive Sells Shares Amid Stock Surge
- Insider Sale Details: Adam Crystal, President of R&D at Tango Therapeutics, sold 20,251 shares on March 5, 2026, for approximately $304,000 at an average price of $15 per share, representing 15.24% of his direct holdings, reducing his position from 132,873 to 112,622 shares.
- Transaction Context: The sale involved only direct ownership without any trades through indirect entities or derivatives, aligning with Crystal's historical pattern of scheduled sales, indicating his awareness of stock price fluctuations.
- Market Reaction: On the same day as the sale, Tango Therapeutics' stock surged 36% following strong Q4 results and pipeline updates, highlighting the market's positive response to clinical data, although insider selling may raise investor concerns.
- Financial Position: Tango Therapeutics holds $343 million in cash, providing a runway into 2028, which offers significant insulation against the inherent risks of clinical-stage oncology, especially as a single failed trial can erase years of gains.
See More
Tango Therapeutics Appoints New CFO and Executives to Accelerate Growth
- Executive Appointments: Tango Therapeutics announced the appointment of Matthew Gall as CFO, Yen-Ching Chua as Chief Development Operations Officer, and Janice Kapty, PhD as SVP of Corporate Strategy and Project Leadership, aiming to enhance the company's leadership in precision cancer drug development.
- Financial Leadership Change: Matthew Gall will take over as CFO effective April 15, 2026, succeeding Daniella Beckman, and with his extensive experience in biotechnology finance and capital raising, he is expected to drive further development of the company's financial strategy.
- Clinical Operations Enhancement: Yen-Ching Chua will assume her role on June 1, 2026, overseeing clinical operations and compliance management, and her global experience from Novocure and Novartis is anticipated to improve the efficiency and quality of the company's clinical trials.
- Project Management Optimization: Dr. Janice Kapty will be responsible for project management of vopimetostat and other therapies, and her background at Arvinas and Bristol Myers Squibb is expected to ensure successful project advancement and strategic implementation.
See More
Revolution's Cancer Drug Shows Promising Results in Trials
- Clinical Trial Results: Revolution's experimental cancer drug daraxonrasib demonstrated statistically significant improvements in progression-free survival and overall survival in patients with metastatic pancreatic ductal adenocarcinoma, with a median survival of 13.2 months compared to 6.7 months for chemotherapy, indicating substantial clinical relevance.
- Market Reaction: Following the announcement, Revolution's shares surged by 41%, reflecting strong market enthusiasm for its research findings, with RBC Capital labeling the drug a 'game changer', potentially attracting more investor interest in the company.
- Competitor Dynamics: Erasca's shares fell by 7% after the positive data from Revolution, despite its own focus on developing therapies for pancreatic cancer, indicating that market confidence in Revolution's results may negatively impact Erasca's outlook.
- Analyst Ratings: While Jefferies maintained a 'Buy' rating and a $21 price target for Erasca, the lack of significant improvement in market expectations suggests that the heightened focus on Revolution could overshadow Erasca's future performance.
See More
Tango Therapeutics Executive Exercises Stock Options
- Stock Option Exercise: Crystal Adam, President of R&D at Tango Therapeutics, exercised 27,000 stock options, resulting in a transaction value of approximately $572,000, which underscores her confidence in the company's future and reflects the strong performance of its stock.
- Transparent Trading Plan: This transaction was executed under a pre-scheduled 10b5-1 trading plan established on October 27, 2025, indicating that these sales were planned in advance rather than being a spontaneous reaction to company news, thereby enhancing investor confidence.
- Ongoing Equity Exposure: Following this transaction, Adam retains 112,622 common shares and 433,500 stock options, demonstrating her continued commitment to the company's performance and investment, which further bolsters market trust in Tango's future.
- Improved Financial Condition: Tango Therapeutics reported a net loss of $101.6 million for 2025, an improvement from the $130.3 million loss in 2024, while ending the year with $343 million in cash and marketable securities, ensuring sufficient funding for its R&D projects in the coming years.
See More
Canaccord Genuity Initiates Coverage of Tango Therapeutics with Buy Rating
- Coverage Initiation: Canaccord Genuity launched coverage of Tango Therapeutics (TNGX) on Thursday with a Buy recommendation and a $30 price target, citing significant upside potential from three trial readouts expected this year.
- Clinical Trial Advantage: Analyst John Newman highlighted Tango's strategy to combine its lead asset vopimetostat with two RAS inhibitors from Revolution Medicines (RVMD) for pancreatic cancer, which is expected to enhance efficacy compared to competitors.
- Sales Forecast: The analyst projects approximately $800 million in peak U.S. sales for vopimetostat in treating MTAP-deleted non-small cell lung cancer, with another readout from a Phase 1/2 monotherapy trial anticipated in 2026.
- Maturity of Data Expected: Newman argued that Tango expects the clinical data to be quite mature by 2026, focusing on overall response rates and progression-free survival, which will provide meaningful support for vopimetostat's clinical profile.
See More
Analysis of Insider Stock Transaction at Tango Therapeutics
- Insider Stock Sale: Adam Crystal, President of R&D at Tango Therapeutics, sold 20,251 shares on March 5, 2026, for a total of $303,765, indicating a continued liquidity management strategy within the company.
- Ownership Proportion Change: This transaction represented 15.24% of Crystal's direct holdings, significantly higher than his earlier median of 3.42%, suggesting an increasing trend in his share sales in recent transactions.
- Company Financial Overview: Tango Therapeutics reported a trailing twelve-month revenue of $62.38 million, with a net income of -$101.59 million; however, its stock price surged 1,220% over the past year, reflecting strong market confidence in its cancer treatment drugs.
- Clinical Trial Progress: The company achieved positive results in clinical trials for MTAP-deleted pancreatic cancer, driving a 36% stock price increase, while holding $343 million in cash, ensuring operational stability during its clinical phase.
See More
Tango Therapeutics Executive Sells Shares Amid Stock Surge
- Insider Sale Details: Adam Crystal, President of R&D at Tango Therapeutics, sold 20,251 shares on March 5, 2026, for approximately $304,000 at an average price of $15 per share, representing 15.24% of his direct holdings, reducing his position from 132,873 to 112,622 shares.
- Transaction Context: The sale involved only direct ownership without any trades through indirect entities or derivatives, aligning with Crystal's historical pattern of scheduled sales, indicating his awareness of stock price fluctuations.
- Market Reaction: On the same day as the sale, Tango Therapeutics' stock surged 36% following strong Q4 results and pipeline updates, highlighting the market's positive response to clinical data, although insider selling may raise investor concerns.
- Financial Position: Tango Therapeutics holds $343 million in cash, providing a runway into 2028, which offers significant insulation against the inherent risks of clinical-stage oncology, especially as a single failed trial can erase years of gains.
See More
